Use of cannabinoids in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-9949937-B2
Application number	US-201715449185-A
Country	US
Kind code	B2
Filing date	Mar 3, 2017
Priority date	Jun 17, 2014
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

First claim

The invention claimed is:

1. A method of reducing seizure frequency in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof clobazam and cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.

2. The method of claim 1 , wherein the administering reduces total convulsive seizure frequency.

3. The method of claim 1 , wherein the patient was administered clobazam prior to administering the combination of the CBD and the clobazam.

4. The method of claim 1 , wherein the CBD comprises Δ9-tetrahydrocannabinol (THC) impurity.

5. The method of claim 1 , wherein the dose of the CBD is at least 15 mg/kg/day.

6. The method of claim 1 , wherein the dose of the CBD is 10 mg/kg/day.

7. The method of claim 1 , wherein the dose of the CBD is 12 mg/kg/day.

8. The method of claim 1 , wherein the dose of the CBD is 14 mg/kg/day.

9. The method of claim 1 , wherein the dose of the CBD is 15 mg/kg/day.

10. The method of claim 1 , wherein the dose of the CBD is 16 mg/kg/day.

11. The method of claim 1 , wherein the dose of the CBD is 18 mg/kg/day.

12. The method of claim 1 , wherein the dose of the CBD is 20 mg/kg/day.

13. The method of claim 1 , wherein the CBD is administered at a dose of 5 mg/kg/day and increased by 2 to 5 mg/kg increments to at least 10 mg/kg/day.

14. A method of treating seizures in a patient with a treatment-resistant epilepsy, which is Dravet syndrome, comprising administering to the patient in need thereof clobazam and cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.

Assignees

• Gw Pharma Ltd

Inventors

• Guy Geoffrey
• Wright Stephen
• Mead Alice
• Devinsky Orrin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/10

  for petit-mal · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title